{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:10:05Z","timestamp":1770484205524,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jneuroim.2012.01.003","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T06:29:41Z","timestamp":1328855381000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["DAF\/CD55 and Protectin\/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis"],"prefix":"10.1016","volume":"244","author":[{"given":"Jindrich","family":"Soltys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Xuebin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2012.01.003_bb0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellimm.2010.07.013","article-title":"Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients","volume":"265","author":"Alegretti","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2009.02.009","article-title":"Interleukin-10 promoter polymorphisms in myasthenia gravis","volume":"210","author":"Alseth","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0015","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1167\/iovs.08-3264","article-title":"Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis","volume":"50","author":"An","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI28622","article-title":"Bypassing complement: evolutionary lessons and future implications","volume":"116","author":"Atkinson","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0025","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/eji.200737973","article-title":"CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity","volume":"38","author":"Bai","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0303-8467(93)90103-N","article-title":"Soluble terminal complement components in human myasthenia gravis","volume":"95","author":"Barohn","year":"1993","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1196\/annals.1405.009","article-title":"Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis","volume":"1132","author":"Christadoss","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0045","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-510X(02)00200-9","article-title":"The role of antibodies in myasthenia gravis","volume":"202","author":"De Baets","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1254.033","article-title":"Immunoregulation in experimental autoimmune myasthenia gravis\u2014about T cells, antibodies, and endplates","volume":"998","author":"De Baets","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0070","series-title":"Myology","first-page":"1755","article-title":"Acquired autoimmune myasthenia gravis","author":"Engel","year":"2004"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0075","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2009-01-198283","article-title":"Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production","volume":"114","author":"Fang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1113\/jphysiol.2001.013381","article-title":"CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9","volume":"539","author":"Farkas","year":"2002","journal-title":"J. Physiol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis\u2014pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0090","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0095","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2567.2000.00066.x","article-title":"Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities","volume":"100","author":"Harris","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0100","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.4049\/jimmunol.161.10.5695","article-title":"Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55)","volume":"161","author":"Hinchliffe","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2249.1999.01062.x","article-title":"Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)","volume":"118","author":"Huang","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0125","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.molimm.2009.07.003","article-title":"Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis","volume":"46","author":"Li","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbrc.2009.03.025","article-title":"Mouse CD4+ CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59","volume":"382","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2567.2001.01287.x","article-title":"Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies","volume":"104","author":"Lin","year":"2001","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0140","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.51.4.933-a","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975","volume":"51","author":"Lindstrom","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/eji.200636755","article-title":"CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms","volume":"37","author":"Longhi","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.10360","article-title":"S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis","volume":"27","author":"Louboutin","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0160","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0165","first-page":"2123","article-title":"Decreased expression of complement regulatory proteins, CD55 and CD59, on peripheral blood leucocytes in patients with type 2 diabetes and macrovascular diseases","volume":"122","author":"Ma","year":"2009","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0175","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1084\/jem.160.5.1558","article-title":"Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes","volume":"160","author":"Medof","year":"1984","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1567-5769(00)00043-6","article-title":"Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases","volume":"1","author":"Miwa","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0185","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0190","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0195","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/(SICI)1097-4598(199701)20:1<92::AID-MUS12>3.0.CO;2-3","article-title":"Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers","volume":"20","author":"Navenot","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0205","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Poea-Guyon","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.gene.6364296","article-title":"Analysis of the promoters and 5\u2032-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes","volume":"7","author":"Qin","year":"2006","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.21319","article-title":"Generation and phenotyping of mCd59a and mCd59b double-knockout mice","volume":"84","author":"Qin","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0295","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1073\/pnas.1111924109","article-title":"C3-dependent mechanism of microglial priming relevant to multiple sclerosis","volume":"109","author":"Ramaglia","year":"2012","journal-title":"Proc. Nat. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0220","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clim.2009.03.523","article-title":"IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4","volume":"132","author":"Shandley","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mus.21371","article-title":"Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?","volume":"40","author":"Sheng","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0240","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.molimm.2006.12.025","article-title":"CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens","volume":"44","author":"Sivasankar","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0245","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/08916930903518081","article-title":"Development of novel therapies for MG: studies in animal models","volume":"43","author":"Souroujon","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0250","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jlb.52.6.652","article-title":"Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation","volume":"52","author":"Terstappen","year":"1992","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2006.07.016","article-title":"Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis","volume":"181","author":"Tuzun","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0260","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"Tuzun","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0265","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1196\/annals.1405.021","article-title":"Autoimmunizing mechanisms in thymoma and thymus","volume":"1132","author":"Willcox","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0270","article-title":"Experimental autoimmune myasthenia gravis in the mouse","volume":"Chapter 15","author":"Wu","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0275","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCRESAHA.108.191361","article-title":"Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex","volume":"104","author":"Wu","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0280","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/CIRCULATIONAHA.108.844589","article-title":"Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice","volume":"121","author":"Wu","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0285","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/00207450601125840","article-title":"High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia gravis","volume":"117","author":"Yapici","year":"2007","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2012.01.003_bb0290","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:19:22Z","timestamp":1759047562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572812000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":59,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0165572812000045"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.01.003","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DAF\/CD55 and Protectin\/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}